Literature DB >> 7635967

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

N Vu-Dac1, K Schoonjans, V Kosykh, J Dallongeville, J C Fruchart, B Staels, J Auwerx.   

Abstract

In view of the evidence linking plasma high density lipoprotein (HDL)-cholesterol levels to a protective effect against coronary artery disease and the widespread use of fibrates in the treatment of hyperlipidemia, the goal of this study was to analyze the influence of fibrates on the expression of apolipoprotein (apo) A-II, a major protein constituent of HDL. Administration of fenofibrate (300 mg/d) to 16 patients with coronary artery disease resulted in a marked increase in plasma apo A-II concentrations (0.34 +/- 0.11 to 0.45 +/- 0.17 grams/liter; P < 0.01). This increase in plasma apo A-II was due to a direct effect on hepatic apo A-II production, since fenofibric acid induced apo A-II mRNA levels to 450 and 250% of control levels in primary cultures of human hepatocytes and in human hepatoblastoma HepG2 cells respectively. The induction in apo A-II mRNA levels was followed by an increase in apo A-II secretion in both cell culture systems. Transient transfection experiments of a reporter construct driven by the human apo A-II gene promoter indicated that fenofibrate induced apo A-II gene expression at the transcriptional level. Furthermore, several other peroxisome proliferators, such as the fibrate, Wy-14643, and the fatty acid, eicosatetraynoic acid (ETYA), also induced apo A-II gene transcription. Unilateral deletions and site-directed mutagenesis identified a sequence element located in the J-site of the apo A-II promoter mediating the responsiveness to fibrates and fatty acids. This element contains two imperfect half sites spaced by 1 oligonucleotide similar to a peroxisome proliferator responsive element (PPRE). Cotransfection assays showed that the peroxisome proliferator activated receptor (PPAR) transactivates the apo A-II promoter through this AII-PPRE. Gel retardation assays demonstrated that PPAR binds to the AII-PPRE with an affinity comparable to its binding affinity to the acyl coA oxidase (ACO)-PPRE. In conclusion, in humans fibrates increase plasma apo A-II concentrations by inducing hepatic apo A-II production. Apo A-II expression is regulated at the transcriptional level by fibrates and fatty acids via the interaction of PPAR with the AII-PPRE, thereby demonstrating the pivotal role of PPAR in controlling human lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7635967      PMCID: PMC185258          DOI: 10.1172/JCI118118

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  83 in total

1.  Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids.

Authors:  A Schmidt; N Endo; S J Rutledge; R Vogel; D Shinar; G A Rodan
Journal:  Mol Endocrinol       Date:  1992-10

2.  Apolipoprotein A-I containing lipoproteins in coronary artery disease.

Authors:  P Puchois; A Kandoussi; P Fievet; J L Fourrier; M Bertrand; E Koren; J C Fruchart
Journal:  Atherosclerosis       Date:  1987-11       Impact factor: 5.162

3.  cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor.

Authors:  T Sher; H F Yi; O W McBride; F J Gonzalez
Journal:  Biochemistry       Date:  1993-06-01       Impact factor: 3.162

4.  The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid.

Authors:  A S Muerhoff; K J Griffin; E F Johnson
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

5.  PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene.

Authors:  O Bardot; T C Aldridge; N Latruffe; S Green
Journal:  Biochem Biophys Res Commun       Date:  1993-04-15       Impact factor: 3.575

6.  LCAT activation properties of apo A-I CNBr fragments and conversion of discoidal complexes into spherical particles.

Authors:  B Vanloo; J Taveirne; J Baert; G Lorent; L Lins; J M Ruyschaert; M Rosseneu
Journal:  Biochim Biophys Acta       Date:  1992-10-30

7.  Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers.

Authors:  K Tokunaga; Y Nakamura; K Sakata; K Fujimori; M Ohkubo; K Sawada; S Sakiyama
Journal:  Cancer Res       Date:  1987-11-01       Impact factor: 12.701

8.  Analysis of transcripts homologous to acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase induced in rat liver by methylclofenapate.

Authors:  S McQuaid; S E Russell; S A Withe; C M Pearson; C R Elcombe; P Humphries
Journal:  Cancer Lett       Date:  1987-10       Impact factor: 8.679

9.  Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers.

Authors:  H Keller; C Dreyer; J Medin; A Mahfoudi; K Ozato; W Wahli
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

10.  Influence of the apoA-II gene locus on HDL levels and fatty streak development in mice.

Authors:  M Mehrabian; J H Qiao; R Hyman; D Ruddle; C Laughton; A J Lusis
Journal:  Arterioscler Thromb       Date:  1993-01
View more
  79 in total

Review 1.  High-density lipoprotein subfractions and risk of coronary artery disease.

Authors:  John Morgan; Christina Carey; Anne Lincoff; David Capuzzi
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

2.  The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.

Authors:  G D Tan; B A Fielding; J M Currie; S M Humphreys; M Désage; K N Frayn; M Laville; H Vidal; F Karpe
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

Review 3.  Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Authors:  Gillian M Keating; Katherine F Croom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements.

Authors:  H Nakshatri; P Bhat-Nakshatri
Journal:  Nucleic Acids Res       Date:  1998-05-15       Impact factor: 16.971

5.  Setting the course for apoAII: a port in sight?

Authors:  Henry J Pownall; Baiba K Gillard; Antonio M Gotto
Journal:  Clin Lipidol       Date:  2013-10

Review 6.  Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.

Authors:  J C Adkins; D Faulds
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

7.  The transcription factor paired-related homeobox 1 (Prrx1) inhibits adipogenesis by activating transforming growth factor-β (TGFβ) signaling.

Authors:  Baowen Du; William P Cawthorn; Alison Su; Casey R Doucette; Yao Yao; Nahid Hemati; Sarah Kampert; Colin McCoin; David T Broome; Clifford J Rosen; Gongshe Yang; Ormond A MacDougald
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

8.  Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

Authors:  L Berthou; N Duverger; F Emmanuel; S Langouët; J Auwerx; A Guillouzo; J C Fruchart; E Rubin; P Denèfle; B Staels; D Branellec
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

10.  Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice.

Authors:  D Sanoudou; A Duka; K Drosatos; K C Hayes; V I Zannis
Journal:  Pharmacogenomics J       Date:  2009-12-01       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.